Document is current
Any future updates will be listed below
-
Authors
Pardons, Marion https://orcid.org/0000-0002-9921-8207
Lambrechts, Laurens https://orcid.org/0000-0002-1415-4591
Noppe, Ytse
Termote, Liesbet https://orcid.org/0009-0006-0510-2868
De Braekeleer, Sofie https://orcid.org/0000-0003-1795-7864
Vega, Jerel
Van Gulck, Ellen
Gerlo, Sarah https://orcid.org/0000-0002-1628-6088
Vandekerckhove, Linos https://orcid.org/0000-0002-8600-1631
- License Information
-
More Information
Article History
Received: 28 August 2024
Accepted: 14 February 2025
First Online: 4 March 2025
Competing interests
: The Authors M.P., L.L., Y.N., L.T., S.D.B., S.G. and L.V. declare no competing interests. The Author E.V.G. declares the following competing interests: this author was an employee of Johnson & Johnson and may be Johnson & Johnson stockholder. The Author J.V. declares the following competing interests: this author was an employee of Arcturus Therapeutics and may be Arcturus Therapeutics stockholder. Johnson & Johnson has a pending patent application related to the Tat-LNP mRNA molecule.
